Phase II Trial of Rituximab Plus 2CdA [cladribine] in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT).

Trial Profile

Phase II Trial of Rituximab Plus 2CdA [cladribine] in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Rituximab (Primary) ; Cladribine
  • Indications MALT lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Nov 2013 Treatment table added.
    • 21 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 21 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top